ClinicalTrials.gg

Program

Phenobarbital

Also written as “Phenobarbital Sodium Injection” and “Sezaby”.

Its studies are mostly in Seizures · Epilepsy, led by 4 companies.

Furthest: phase 4, since Jan 20, 20114 company-led studies, 1 open or runningNext primary completion: Mar 2028 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hikma Pharmaceuticals10 open or runningphase 3since Jan 20, 2011Jan 20, 2011none ahead
NEMA Research10 open or runningphase 3since Mar 23, 2020Mar 23, 2020none ahead
PharPoint Research10 open or runningphase 3since Jul 17, 2018Jul 17, 2018none ahead
Sun Pharmaceutical Industries11 open or runningphase 4since Oct 13, 2026Oct 13, 2026Mar 2028phase 4 · NCT07923734

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 20, 2011First study: phase 3 study in EpilepsyNew to Hikma PharmaceuticalsHikma Pharmaceuticals · NCT01284556 · 314 enrolled · United States, Puerto Rico
  2. Jul 17, 2018PharPoint Research's first study: phase 3 study in Neonatal SeizureNew to PharPoint ResearchPharPoint Research · NCT03602118
  3. Mar 23, 2020NEMA Research's first study: phase 3 study in Epilepsy, Benign NeonatalNew to NEMA ResearchNEMA Research · NCT04320940 · 4 enrolled · United States, Jordan
  4. Oct 13, 2026Sun Pharmaceutical Industries's first study: phase 4 study in Neonatal SeizureNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT07923734 · 45 planned · United States

Ahead

  1. Mar 2028Primary completion: phase 4 study in Neonatal SeizureSun Pharmaceutical Industries · NCT07923734

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07923734Neonatal Seizure · United States4Not yet recruitingSun Pharmaceutical IndustriesMar 202845
NCT04320940Epilepsy, Benign Neonatal · United States, Jordan3TerminatedNEMA ResearchFeb 1, 20234
NCT03602118Neonatal Seizure3WithdrawnPharPoint ResearchMay 1, 20210
NCT01284556Epilepsy · United States, Puerto Rico3CompletedHikma PharmaceuticalsJan 2013314

How it is read

Names in the registry

  • “Phenobarbital Sodium Injection”, 2 entries
  • “Sezaby”, 1 entry
  • “Phenobarbital”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.